Communiqués Simris Group AB

Actions

SIMRIS B

SE0008091664

Transformation des aliments

Marché Fermé - Nasdaq Stockholm Autres places de cotation 16:32:59 31/07/2026			Varia. 5j.	Varia. 1 janv.
0,1150 ^SEK	-10,51%		-9,80%	+168,69%

15/07	Simris Group AB annonce la nomination d'Andreas Pahl au poste de directeur général de Simris Biologics GmbH, à compter du 15 juillet 2026	CI
13/05	Simris Group AB (PUBL) publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

13/07	Simris : A holder of warrants in Simris Group AB (publ) has declared his intention to exercise 3.3 million warrants amounting to total proceeds of EUR 15,000	PU
24/06	Simris : Bulletin from Simris Group AB’s annual general meeting	PU
28/02	Simris : Year-end Report Q4 2025	PU
28/11	Simris : enters into bridge loan agreement	PU
12/11	Simris : Interim Report Q3 2025	PU
10/11	Simris : announces leadership transition - Daniel Kubitza appointed interim CEO	PU
27/07/25	Simris () : resolves on a directed issue of convertible debentures of EUR 678,000 and amends existing loan facilities	PU
02/06/25	Simris : Signs Non-Binding Concept Sheet for Potential Antibody-Drug Conjugate Collaboration	PU
28/05/25	Simris : Bulletin from Simris Group AB’s annual general meeting	PU
20/01/25	Simris : Bulletin from Simris Group AB’s Extraordinary General Meeting	PU
13/03/23	SIMRIS ALG AB CONFIRMS NAME CHANGE TO SIMRIS GROUP AB	AQ
06/03/23	Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its Adc Payload Technology	GL
06/03/23	BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING OF SIMRIS ALG AB (PUBL)	AQ
28/02/23	SIMRIS ALG AB SIGNS PARTNERSHIP AGREEMENT WITH LONZA LTD TO PROMOTE ITS ADC PAYLOAD TECHNOLOGY	AQ
20/02/23	Equity Research \| SIMRIS ALG: Transforming to build an integrated multi-vertical microalgae and cyanobacteria company	AQ
11/11/22	Equity Research \| SIMRIS ALG: Ready to execute on a three-pronged roadmap to capture the most high-value opportunities	AQ
07/09/22	Equity Research \| SIMRIS ALG: Cyano deal jumpstarts venture into Biopharma with sight set on the novel ADC market	AQ
07/09/22	SIMRIS ALG: Video Interview with SIMRIS CEO Julian Read and CYANO BIOTECH Co-Founder Dan Enke	AQ
18/08/22	Equity Research \| SIMRIS ALG: Accelerating entry into high-value biopharma with acquisition of Cyano Biotech	AQ
05/08/22	Equity Research \| SIMRIS ALG: Targeting biopharma to exploit highest value verticals in the microalgae and cyanobacteria space	AQ
25/04/22	Simris Alg fueling up for incoming CEO to build on accelerating momentum	AQ
22/04/22	Simris Alg interim report January-March 2022	AQ
20/04/22	Simris Alg publishes its annual report for 2021	AQ
20/04/22	Simris Alg publishes investment memorandum regarding Rights Issue	AQ
16/12/21	Simris set for commercial acceleration in 2022 \| See interview with Chairman Steven Schapera	AQ